First PROTECT patient treated with protons at Paul Scherrer Institute in Villigen, Switzerland.
University Hospital Zurich has in collaboration with the Paul Scherrer Institute for the first time in Switzerland treated an esophageal cancer patient with proton radiotherapy.
Switzerland is the third country to start treating PROTECT patients. This also marks the 25th patient treated in the PROTECT study. Read more on PSI's website A Swiss premiere Proton radiotherapy to treat oesophageal cancer | Our Research | Paul Scherrer Institut (PSI)
- PROton versus photon Therapy for Esophageal Cancer – a Trimodality strategy (PROTECT) compares the clinical outcomes of proton therapy and state-of-the-art photon radiotherapy for locally advanced esophageal cancer.
- PROTECT study is developed by the European Particle Therapy Network (EPTN)
- A total of 396 patients are expected to be included in the randomized study with completion expected by 2027.
- This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101008134. The JU receives support from the European Union’s Horizon 2020 research and innovation program, EFPIA, Varian - a Siemens Healthineers company, and IBA worldwide.
- Damien Weber, Head of CPT, PSI, Villigen, CH.
- Email: firstname.lastname@example.org
- Panagiotis Balermpas, Principal Investigator, USZ, Zurich, CH.
- Email: email@example.com
- Marianne Nordsmark, Chief Investigator, Aarhus University Hospital, DK.
- E-mail: firstname.lastname@example.org
- Website: https://www.protect-trial.eu/
- Twitter (X): @PROTECT_trial